HR 19024
Alternative Names: HR-19024Latest Information Update: 14 Sep 2022
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Microtubule protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 10 Aug 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Monotherapy) in China (IV) (NCT05463432)
- 27 Jul 2022 Preclinical trials in Solid tumours in China (IV) on or before July 2022
- 19 Jul 2022 Shanghai Hengrui Pharmaceutical plans a phase-I trial for solid tumours (Monotherapy, Late-stage disease) in July 2022 (IV, infusion) (NCT05463432)